RE: RE: RE: Back to the Roots ???? I totally agree with you on the
.24…what I mean is if you estimate that phase III will require 25-35 million to execute and you divide this by the total outstanding you are very close to the
.24 range.
Management and the potential partner know that if they don’t get phase III approval the value of SSS goes down dramatically and if they do the value shoots up. So I’m thinking that the partner offered a share price close to 0.24 to buyout the entire company before the FDA meeting. If board of directors accepted this offer and Phase III does get approved, the partner makes a killing. If SCT doesn’t get phase III approval well the partner probably paid FMV for the SCT's IP. This is where one can speculate on Dr.Moore’s sudden departure i.e., not too happy with the deal.
Baylor (A.K.A. a pimpled faced teenager pumping SSS) lol